Multiple Myeloma and Other Plasma Cell Neoplasms

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology, Oncology
Cover of the book Multiple Myeloma and Other Plasma Cell Neoplasms by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319255866
Publisher: Springer International Publishing Publication: February 16, 2018
Imprint: Springer Language: English
Author:
ISBN: 9783319255866
Publisher: Springer International Publishing
Publication: February 16, 2018
Imprint: Springer
Language: English

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

More books from Springer International Publishing

Cover of the book Artificial Intelligence and Soft Computing by
Cover of the book Criminal Justice and Mental Health by
Cover of the book Fear and Uncertainty in Europe by
Cover of the book Virtualized Cloud Data Center Networks: Issues in Resource Management. by
Cover of the book Homogeneous Catalysis with Renewables by
Cover of the book International Scholarships in Higher Education by
Cover of the book Challenges of a Rechargeable Magnesium Battery by
Cover of the book Biology, Productivity and Bioenergy of Timber-Yielding Plants by
Cover of the book Measurements of the X c and X b Quarkonium States in pp Collisions with the ATLAS Experiment by
Cover of the book Neoclassical Physics by
Cover of the book Advances in Computational Intelligence by
Cover of the book Anatomy and Exposures of Spinal Nerves by
Cover of the book Robotic Manipulators and Vehicles by
Cover of the book Ethics and Neuromarketing by
Cover of the book Advances in Cryptology – ASIACRYPT 2017 by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy